Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03365791
Title PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

sarcoma

lymphoma

Advanced Solid Tumor

neuroendocrine tumor

diffuse large B-cell lymphoma

gastric adenocarcinoma

esophagus adenocarcinoma

ovary adenocarcinoma

lung small cell carcinoma

prostate adenocarcinoma

Therapies

Ieramilimab

Spartalizumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.